DRAVP ID  DRAVPc027

Name   Cilgavimab(AZD1061)

Sequence  Not available

Molecular Formula  C6626H10218N1750O2078S44

Condition/Disease  COVID-19

Group  Approved

Type  Antibody

Description  Cilgavimab is an extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Cilgavimab is not approved for any indication by the FDA. Cilgavimab, in combination with tixagevimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,5 and was approved in Canada soon after, on April 14, 2022.

Active sequence/Structure 

DrugBank Accession Number  DB16393

Pubchem ID  440964522

CHEMBL ID  Not Available

UNII  1KUR4BN70F

CAS  2420563-99-9

Reference  32651581  34548634